The efficacy of thiazolidin-4-ones as synthons for diverse biological small molecules has given impetus to antibacterial studies. Our work aims to synthesize novel bioactive thiazolidin-4-ones using nano-MoO 3 for the first time. The compelling advantage of using nano-MoO 3 is that the recovered nano-MoO 3 can be re-used thrice without considerable loss of its catalytic activity.
Introduction
Transition metal oxides are extensively used in many organic reactions owing to their advantage over their counterparts. 1 The use of co-ordination compounds with variety of metals have replaced acids or bases with satisfactory yields. Often, use of acid or bases results in low product yield due to reverse/side reactions and the use of organic solvents increases the difficulty in catalyst recovery. 2 Molybdenum oxide (MoO 3 ) is projected as potential nanostructure because of its wide range of stoichiometric, structural, thermal, chemical and optical properties. [3] [4] [5] MoO 2 or MoO 3 supported catalysts are reported to efficiently catalyze various organic reactions including Beckmann rearrangement, 6 nitration of aromatics, 7 oxidation of ammonia to elemental N 2 and synthesis of diphenyl carbonate from dimethyl carbonate and phenol. 8 In the present work, we report the use MoO 3 for the synthesis of novel thiazolidin-4-ones and analyzed the anti-bacterial activity of new structures.
Antibiotic resistance is a major concern in contemporary medicine and has emerged as one of the prominent public health issues of the 21 st century, 9 particularly as it pertains to pathogenic organisms such as Salmonella typhi and Klebsiella pneumoniae. 10 S. typhi and K. pneumoniae are the pathogenic gram-negative bacterial strains, where former is predominately found in the intestinal lumen and latter in the gastrointestinal tract and in naso-pharynx.
Diverse species of pathogenic gram-negative bacteria use secretion systems to export a variety of protein toxins and virulence factors that help to establish and maintain infection.
Disruption of such secretion systems is a potentially effective therapeutic strategy against these bacterial infections. In order to develop small molecule antibacterials, we subjected the title compounds to a high-throughput screen and identified a tris-aryl substituted 2-imino-5-arylidenethiazolidin-4-one, compound 3b, as an inhibitor of the Type III secretion system.
Expansion of this chemotype enabled us to define the essential pharmacophore for Type III secretion inhibition by this structural class. 11, 12 In continuation of our work to synthesize and explore pharmacological properties of various class of heterocycles, [13] [14] [15] [16] [17] [18] [19] [20] herein we report the application of MoO 3 nanoparticles in the synthesis of novel thizolidin-4-ones, followed by their use as antibacterial agents against S. typhi 
Selection of the reaction system and optimization of reaction conditions:
Initially, we synthesized thiazolidin-4-ones by the reaction of p-anisaldehyde (1a) with β-naphthyl amine (2a) using various methodologies as reported in table 1 and came up with a stabilized protocol using MoO 3
Scheme 1a: Synthesis of 2-(4-methoxyphenyl)-3-(naphthalen-1-yl)thiazolidin-4-one 22 We found that the use of nano MoO 3 in ethanol is the system ideal for the ring forming condensation reaction. The reactions with other methodologies resulted in low yields, while nano-MoO 3 in refluxing ethanol led to comparatively high yield of the product.
Table1:
Comparative study on different methods and solvent for thiazolidin-4-one formation. To achieve a stabilized reaction system for thiazolidin-4-ones synthesis, we considered the reaction between p-anisaldehyde (1 eq) (1a) and β-naphthyl amine (1 eq) (2a) (Scheme 1a).
The reaction between 1a and 2a in the presence of nano MoO 3 (1 eq) in ethanol at 70 ºC resulted in the product (3a) yield of 52% after 6.2 h ( Table 2 , entry 1). The increase in the amount of nano MoO 3 (1.8 eq) resulted in the increase of product yield to 94% within 4 h ( Table 2, Subsequently, we attempted to explore a better solvent system for the reaction with various polar and non-polar solvents. The reaction was monitored in solvents such as acetonitrile: water, ethanol : water, n-butanol, THF, benzene and toluene. All the tested solvent systems displayed an inferior product yield (3a) than that of ethanol (Table 2 entries 5-11). a Yield of the product after column chromatography.
We next analyzed the reusability of nano MoO 3 , which was used in the synthesis of thiazolidin-4-one as represented in scheme 1a. After the completion of reaction every time, filtered residue containing nano MoO 3 was washed with ethanol and reused for next run with fresh p-anisaldehyde, 2-naphthyl amine and thiaglycolic acid. We observed the considerable decrease in the yield of the product on reuse of nano MoO 3 after third run. The second and third run resulted in the yield of 74 % and 65 % respectively.
We finally used the optimized reaction conditions to prepare the novel series of thiazolidin-4-ones in which we used aryl/heteroaryl aldehydes with heteroaryl amines and thioglycolic acid (Scheme 1b). Most of the aldehydes and amines bearing various electron donating and electron withdrawing substituents resulted in products with high yields (Table 2 entries 2-15).
Scheme 1b: Synthesis of novel series of thiazolidin-4-ones 3(b-o). 
Anti-bacterial activity
The minimum inhibitory concentration (MIC) of the compound, which is required for inhibition of bacterial growth by the compounds 3(a-o), along with the MIC of a reference drug (Gentamicin) are shown in Table 4 . Our results show that, of the benzisoxazole and indole series, compound 3b, 3c (benzisoxazole series) and compound 3l (indole series) showed significant anti-bacterial activity towards S. typhi with zone of inhibition values of 23 mm, 17 mm and 16 mm, respectively and MIC values of 300 µg/mL, 400 µg/ml and 800 µg/ml respectively.
Compounds 3e and 3l were found to be effective against K. pneumoniae with zone of inhibition values of 14 mm and 14 mm, respectively, and MIC values of 700 µg/ml and 400 µg/ml respectively. 
Cheminformatics
Human protein targets were predicted for the most bioactive compound 3b, which was shown to have an inhibitory effect on the growth of S. Typhi. 23 The predicted target, Potassium voltagegated channel subfamily A member 5, with a corresponding probability value of 0.069 is shown in 24, 25 we hypothesise the latter target, the DNA translocase FtsK (Uniprot ID:
Q8ZQD5.1) as potentially being the target that is responsible for growth inhibition of S.typhi.
In addition, in order to investigate the bioactivity profile of compounds similar to compound 3b and thus to understand the target prediction of compound 3b from the chemical side, bioactivity data was retrieved for 34 compounds from ChEMBL with a similarity of 70% or higher to compound 3b, covering 39 unique protein targets. Of these, 32 targets had a PANTHER 
Rationalization of the putative target of the bioactive thiazolidin-4-ones via in silico molecular docking
Given that our cheminformatics approaches present the predicted putative target, namely the DNA translocase FtsK, as a mode-of-action hypothesis, we subsequently performed molecular docking studies to understand the ligand-protein interactions in detail. FtsK is a conserved DNA translocase, whose action is crucial in bacterial cell division during the late stages of chromosome segregation. 29, 30 18, 19 . In addition, deletion or over expression of FtsK can result in the inhibition of cell division. 20 The docking scores (DS) of the docked compounds with the FtsK motor domain are summarised (Table 4) 
Conclusions
In this study, we developed synthetic method for novel bioactive thiazolidine-4-ones by condensation of aryl/heteroaryl aldehydes, heteroaryl amines using nano MoO 3 for the first time.
The antibacterial activity of the synthesised thiazolidin-4-ones against two pathogenic strains, namely S.typhi and K.pneumoniae revealed that compound 3b showed significant inhibitory activity towards S.typhi, with an activity comparable to gentamicin. Furthermore, in silico human target prediction for compound 3b predicted the FtsK domain of DNA translocase as a putative target. In addition, our molecular docking analysis suggests that the highly active compound 3b strongly interacts with the FtsK motor domain, when compared to other structurally related compounds, hereby indicating that it may disrupt chromosome segregation and thereby inhibit the cell division of S.typhi in culture.
Experimental Section

Synthesis of nano-MoO 3
Nano MoO 3 has been synthesized according to reported procedure.
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Synthesis of novel thiazolidin-4-ones
All reagents were commercially available reagent grade and were used without further purification. Thin layer chromatography (TLC) was conducted on 0.25 mm silica gel plates (60F254, Merck). Column chromatography separations were obtained on silica gel (200-400 mesh). IR spectra were recorded on Bruker FTIR spectrophotometer. 1 H NMR spectra were recorded on a BrukerAvance-400 instrument (few on Agilent NMR instrument) in DMSO-d 6 (few in CDCl 3 ) solvent. 13 C NMR spectra were obtained on an Agilent NMR instrument at 100
MHz in DMSO-d 6 solvent (few in CDCl 3 ). Chemical shifts were expressed in ppm downfield relative to TMS. Mass spectra were recorded on an Agilent LC-MS. The elemental analysis was carried out using an Elemental Vario Micro Cube CHN analyzer.
General procedure
Aryl/heteroaryl aldehyde (1 eq), heteroaryl amine (1 eq) and thioglycolic acid (1.5 eq) were refluxed in ethanol in presence of nano MoO 3 (1.8 eq) for stipulated time (Table 3) . Reaction was monitored for its completion by thin layer chromatography using hexane:ethylacetate (7:3) mobile phase. After the completion of the reaction, it is brought to room temperature, filtered through Whatman filter paper 42 and solvent was removed under vacuum to get the novel thiazolidin-4-ones (3a-o). The pure product was obtained by column chromatography using ethyl acetate and n-hexane and ethyl acetate (about 15%) as eluent.
Spectral Characterization of novel thiazolidin-4-ones 3(b-o)
3-(benzo[d]isoxazol-3-yl)-2-(3-methoxyphenyl) thiazolidine-4-one (3b):
IR ( 
3-(benzo[d]isoxazol-3-yl)-2-(4-nitrophenyl) thiazolidine-4-one (3c):
3-(benzo[d]isoxazol-3-yl)-2-(2-nitrophenyl) thiazolidine-4-one (3d):
3-(benzo[d]isoxazol-3-yl)-2-(3-nitrophenyl) thiazolidine-4-one (3e):
3-(benzo[d]isoxazol-3-yl)-2-(4-fluorophenyl) thiazolidine-4-one (3f):
3-(5-bromobenzo[d]isoxazol-3-yl)-2-(4-bromophenyl) thiazolidin-4-one (3h):
3-(5-bromobenzo[d]isoxazol-3yl)-2-(2-butyl-4-chloro-1H-imidazol-5-yl) thiazolidine-4-one (3i):
3-(2-methyl-1H-indol-5-yl)-2-(3-nitrophenyl) thiazolidine-4-one (3j):
2-(4-bromophenyl)-3-(2-methyl-1H-indol-5-yl) thiazolidine-4-one (3k):
2-(2-butyl-4-chloro-1H-imidazol-5-yl)-3-(2-methyl-1H-indol-5-yl) thiazolidine-4-one (3l):
2-(4-nitrophenyl)-3-(1-oxo-1,3-dihydroisobenzofuran-5-yl)thiazolidin-4-one (3n):
Antibacterial studies
The antibacterial assay was performed via serial dilution method and agar diffusion method at different concentrations new compounds. 31 All synthesized small molecules were screened for their in vitro antibacterial activity against gram-negative bacteria, S.typhi (MTCC 733) and K.pneumoniae (MTCC 661) by the agar diffusion method at different concentration. The stock cultures of bacteria were revived by inoculating them in broth media and were grown at 37 ºC for 18 hours. The agar plates of the above media are prepared and each plates were inoculated with bacterial strains. The wells were made in the plates using cork borer and different concentrations of compounds were added and diameter of the inhibition zone was noted. The MIC values were calculated using serial dilution method.
Cheminformatics analysis
In silico target prediction
Given the constantly increasing amount of bioactivity data available, we attempted to rationalise the mode-of-action of the experimentally active compounds using in silico approaches, which is currently the topic of many chemogenomics studies. 32 In order to achieve this, we applied the Parzen-Rosenblatt Window classifier (with the smoothing parameter having set to 0.9) to predict potential targets for the compounds which were experimentally tested. 23 This classifier was trained on a large dataset comprising approximately 190,000 bioactive compounds covering 477 human protein targets. Normalised target likelihood was calculated for each predicted target by comparing the predicted targets in the dataset used in this study to target predictions of a background dataset comprising 3,000 compounds in total from PubChem, 33 GDB13 34 and ChEMBL 35 with 1,000 compounds randomly selected from each database. All targets with a probability of 0.05 or higher were considered as predicted in both cases. For each predicted target, the normalised likelihood was determined by dividing the relative frequency of the predicted target for the compound by the relative frequency of the prediction of same target in the background dataset:
Subsequently, a DELTA-BLAST protein domain similarity search 36 was performed on the predicted human targets using their respective Swiss-Prot 37 identifiers in order to extrapolate from human protein targets to protein targets in S.typhi. DELTA-BLAST is a protein sequence alignment algorithm which aims to find homologous proteins across species based on the similarity of their protein domains. The concept of assessing proteins based on the similarity of their domains has been previously explored to predict homologous targets 38 and has also been proven suitable for the prediction of novel targets for M.tuberculosis. 39 In our case, the DELTA-BLAST search was limited to S.typhi (taxid:90371) and the UniProtKB/Swiss-Prot database 37 was chosen as the search database due to its high quality of manually curated proteins. All searching parameters were set to their respective default values (i.e. the expect threshold was set to 0.01, word size was set to 3 and the maximum number of matches in a query range set to 0) and standard scoring parameters were used, namely the BLOSUM62 position specific scoring matrix, the existence of a gap was assigned a score cost of 11, whereas gap extension costs were set to 1. Compositional adjustments were set to composition-based statistics and the DELTA-BLAST threshold was set to 0.05.
Comparison of bioactivity of compounds similar to compound 3b
Bioactivity data for compounds with a similarity of 70% or higher to compound 3b, based on the Accelrys Direct similarity measure employed by ChEMBL, 40 were retrieved from ChEMBL. 35 Bioactivity data for only compounds with an AC 50 , EC 50 , IC 50 or potency value of 10 µM or better and a ChEMBL confidence score of 8 or higher were considered. Subsequently, the set of targets (including duplicates) retrieved were categorised in terms of the PANTHER 26 biological processes they are involved in.
Molecular docking:
Molecular modelling was performed in InsightII, Discovery Studio (DS) Version 2.5. The structure and mechanism of hexameric FtsK, a double-stranded DNA was adopted in our docking studies (with the water molecules removed). The generated ligand conformations were energy minimized with the CHARMM force field using steepest descent until convergence.
During the final step of docking using the LigandFit program (version 2.5), all the minimised conformations were compared and redundant conformations were discarded. Each docked pose was evaluated for its fitness using multiple scoring functions (LigScore1, LigScore2, -PLP1, -PLP2, Jain, -PMF, Ludi 1, Ludi 2, Ludi 3, -PMF04, DOCK SCORE). Subsequently, the multiple scores obtained from the calculations of LigandFit were prioritized for each docked pose. The docked poses of active compounds among 3(b-o) with the hydrophobic sites of the FtsK motor domain with the highest consensus score was selected as the favorable conformation and their complex structure was prepared.
